Phibro Animal Health outlines 2026 CEO transition to Dani Bendheim

Phibro Animal Health Corporation is planning a leadership transition.

Rhea-AI Filing Summary

Phibro Animal Health Corporation is planning a leadership transition. Jack C. Bendheim, currently Chairman, Chief Executive Officer and President, will resign from the CEO and President roles effective July 1, 2026, and move into a new managerial position as Executive Chairman. He will remain Chairman of the Board and continue to provide strategic oversight and work with the executive team.

On that same date, Daniel (Dani) Bendheim, age 53 and currently Executive Vice President, Corporate Strategy, will become Chief Executive Officer and President. He has been with the company since 1997, has held multiple senior roles including President of Performance Products, and has served on the Board since November 2013. Dani Bendheim is Jack Bendheim’s son and part of the Bendheim family investment vehicle BFI Co., LLC. Both Jack and Dani Bendheim are expected to enter into new or amended employment agreements before the transition becomes effective.

Insights

Corporate governance and succession planning analyst

Phibro discloses a planned CEO succession with strong internal continuity.

Phibro Animal Health Corporation has outlined a clear succession plan in which longtime leader Jack C. Bendheim will step down as Chief Executive Officer and President on July 1, 2026, while remaining Chairman and becoming Executive Chairman. This maintains his influence on strategic oversight and supports continuity at the board and management levels.

Daniel (Dani) Bendheim, currently Executive Vice President, Corporate Strategy, will assume the Chief Executive Officer and President roles on the same effective date. The filing highlights his approximately 28 years with the company and prior leadership positions, which suggests deep familiarity with operations and strategy. The family relationship between Jack and Dani Bendheim, and their links to BFI Co., LLC, underline the company’s family-influenced governance structure, which may shape decision-making.

The planned execution date and the intention for both executives to enter into new or amended employment agreements provide a defined roadmap for the transition. Subsequent disclosures about the final employment terms and any changes in responsibilities or governance structures will further clarify how this leadership change aligns with the company’s longer-term strategic direction.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What leadership change did Phibro Animal Health Corporation (PAHC) announce?

Phibro Animal Health Corporation announced that Jack C. Bendheim will resign as Chief Executive Officer and President, effective July 1, 2026, and will transition to the role of Executive Chairman while remaining Chairman of the Board.

Who will become the new CEO and President of Phibro Animal Health (PAHC)?

On July 1, 2026, Daniel (Dani) Bendheim, currently Executive Vice President, Corporate Strategy, will assume the roles of Chief Executive Officer and President of Phibro Animal Health Corporation.

What is Daniel (Dani) Bendheim’s background at Phibro Animal Health (PAHC)?

Dani Bendheim has about 28 years with the company, having joined in 1997. He has served as Vice President of Business Development, President, Performance Products, and since March 2014 as Executive Vice President, Corporate Strategy, and has been a Board member since November 2013.

How are Jack C. Bendheim and Daniel (Dani) Bendheim related and what is BFI Co., LLC?

Dani Bendheim is the son of Jack C. Bendheim and the brother of director Jonathan Bendheim. Together with certain family members, he is a Manager of BFI Co., LLC, an investment vehicle for the Bendheim family’s economic rights in Phibro stock.

Will Jack and Dani Bendheim have new employment agreements at Phibro Animal Health?

Yes. The company states that each of Jack C. Bendheim and Daniel (Dani) Bendheim will enter into a new or amended employment agreement prior to the July 1, 2026 effective date of the leadership transition.

Did Phibro Animal Health (PAHC) issue a press release about the CEO transition?

Yes. On December 18, 2025, the company issued a press release announcing Jack C. Bendheim’s resignation as CEO and President and the appointment of Dani Bendheim as his successor, and this press release is furnished as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 04:20 PM Learn about SEC filing dates

false 0001069899 0001069899 2025-12-16 2025-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 18, 2025 (December 16, 2025)

Phibro Animal Health Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

Delaware		001-36410		13-1840497
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Glenpointe Centre East, 3rd Floor

300 Frank W. Burr Boulevard, Suite 21

Teaneck, New Jersey 07666-6712

(Address of Principal Executive Offices, including Zip Code)

(201) 329-7300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		PAHC		NASDAQ Stock Market

Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

On December 18, 2025, Phibro Animal Health Corporation (“Phibro” or the “Company”) announced that Jack C. Bendheim, the current Chairman of the Board of Directors of the Company (the “Board”), Chief Executive Officer and President, will resign from his position as Chief Executive Officer and President, effective July 1, 2026 (the “Effective Date”). On the Effective Date, Mr. Jack C. Bendheim will assume a new managerial role as Executive Chairman and will continue to support strategic oversight and work closely with the executive leadership team. Mr. Jack C. Bendheim will continue to serve as the Chairman of the Board of Directors of the Company.

On the Effective Date, Daniel (Dani) Bendheim, age 53, the Company’s current Executive Vice President, Corporate Strategy, will assume the role of Chief Executive Officer and President of the Company. Mr. Dani Bendheim brings approximately 28 years of knowledge of the Company’s business into his new role, having first joined the Company in 1997. He was appointed the Company’s Vice President of Business Development in 2001, appointed President, Performance Products in 2004, and then appointed to his current role as Executive Vice President, Corporate Strategy in March 2014. He was elected as member of the Board in November 2013.

Mr. Dani Bendheim is the son of Mr. Jack C. Bendheim, and the brother of Mr. Jonathan Bendheim, a member of the Board, and, together with certain other family members, is a Manager of BFI Co., LLC (“BFI”), an investment vehicle of the Bendheim family, with respect to the economic rights pertaining to shares of Company stock owned by BFI. For a description of Mr. Dani Bendheim’s family relationships with other directors and executive officers and for related party transactions, please see his biography under the heading “Executive Officers” and “Certain Relationships and Related Party Transactions” in Phibro’s Definitive Proxy Statement filed with the SEC on September 19, 2025, which sections are incorporated by reference herein.

Each of Mr. Dani Bendheim and Mr. Jack C. Bendheim will enter into a new or amended employment agreement prior to the Effective Date.

ITEM 7.01 REGULATION FD DISCLOSURE.

On December 18, 2025, the Company issued a press release announcing Mr. Jack C Bendheim resigning from his role as Chief Executive Officer and President of the Company, and the appointment of Mr. Dani Bendheim as his successor to such roles, effective as of July 1, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 and in the press release is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release, dated December 18, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PHIBRO ANIMAL HEALTH CORPORATION
	Registrant
Date: December 18, 2025
	By:	/s/ Judith Weinstein
	Name:	Judith Weinstein
	Title:	Senior Vice President, General Counsel and Corporate Secretary